Emergence of a Streptococcus pneumoniae clinical isolate highly resistant to telithromycin and fluoroquinolones

J Clin Microbiol. 2005 Nov;43(11):5800-3. doi: 10.1128/JCM.43.11.5800-5803.2005.

Abstract

Streptococcus pneumoniae is a major pathogen causing community-acquired pneumonia and acute bronchitis. Macrolides, fluoroquinolones (FQs), and, recently, telithromycin (TEL) constitute primary therapeutic options, and rare cases of resistance have been reported. In this report, we describe the emergence of an S. pneumoniae clinical isolate with high-level TEL resistance (MIC, 256 microg/ml) and simultaneous resistance to FQs. Ongoing studies are oriented to elucidate the precise mechanism of resistance to TEL.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Amino Acid Sequence
  • Bacterial Proteins / genetics
  • Base Sequence
  • Deoxyribonucleases, Type II Site-Specific / genetics
  • Drug Resistance, Multiple, Bacterial
  • Electrophoresis, Gel, Pulsed-Field
  • Female
  • Fluoroquinolones / pharmacology
  • Humans
  • Ketolides / pharmacology
  • Molecular Sequence Data
  • Pneumococcal Infections / microbiology*
  • Protein Synthesis Inhibitors / pharmacology
  • Sequence Alignment
  • Streptococcus pneumoniae / drug effects
  • Streptococcus pneumoniae / isolation & purification*

Substances

  • Bacterial Proteins
  • Fluoroquinolones
  • Ketolides
  • Protein Synthesis Inhibitors
  • CCCGGG-specific type II deoxyribonucleases
  • Deoxyribonucleases, Type II Site-Specific
  • telithromycin